Robert EJ Ryder's research while affiliated with Sandwell and West Birmingham Hospitals NHS Trust and other places

Publications (13)

Article
Aims: EndoBarrier is a 60cm duodenal–jejunal bypass liner endoscopically implanted for up to one year and designed to mimic the by‐pass part of Roux‐en‐Y bariatric surgery. We aimed to assess the safety and efficacy of EndoBarrier in patients with suboptimally‐controlled diabesity. Methods: Between July 2013 and November 2017 we implanted 90 EndoBa...
Article
Background & aims To assess the impact of pre-admission renin-angiotensin-aldosterone system inhibitor (RAASi) and statin use on mortality following COVID-19 hospitalization in adults with pre-existing diabetes. Methods Retrospective cohort study of adults with diabetes admitted to ninety-nine participating hospitals in the United Kingdom, France...
Article
Background: People with diabetes and coronavirus disease 2019 (COVID-19) have a significantly greater risk of death and/or intensive care unit (ICU) admission. The Association of British Clinical Diabetologists (ABCD) recently audited outcomes for people hospitalised in the UK with diabetes and COVID-19. Methods: The ABCD COVID-19 and diabetes audi...
Article
Sodium-glucose linked transporter 2 inhibitors (SGLT2i) have been demonstrated to improve cardiovascular outcomes. In particular, SGLT2i appear to be beneficial in improving heart failure outcomes in people with and without diabetes. The aim of this review was to synthesis current evidence from randomised controlled trials (RCTs) comparing SGLT2i t...
Article
We describe the rationale, aims and objectives and the methodology of data collection for the ABCD nationwide audit of individuals admitted to hospital with coronavirus (SARS-CoV-2; COVID-19) and diabetes. The audit was inspired and undertaken by the urgent need to understand the clinical course of COVID-19 in patients with diabetes admitted to hos...
Article
Introduction: Canagliflozin was initially approved for use in the UK in March 2013. Randomised control trial evidence has demonstrated multiple beneficial effects. Many of these are present at initial follow-up and within 26 weeks of randomised control trial data. Our aim was to assess whether the beneficial effects of canagliflozin on multiple cli...
Article
People with type 2 diabetes mellitus experience an increased prevalence of non-alcoholic fatty liver disease (NAFLD) compared with the general population and often with worse outcomes. As part of the ABCD Liraglutide Nationwide Audit Programme, we obtained and analysed data from 2009 to 2018 to assess the impact of liraglutide on alanine aminotrans...
Article
Full-text available
Aims: EndoBarrier is a 60 cm proximal intestinal liner, endoscopically implanted for up to 1 year, designed to mimic the bypass aspect of Roux-en-Y gastric bypass surgery. We aimed to assess its safety and efficacy in patients with advanced diabesity.Methods: Since October 2014 we have implanted 62 Endo-Barriers in our NHS service. By November 2018...
Conference Paper
Introduction New, effective treatments are needed urgently to combat the global diabesity pandemic. Our institution led a UK multicentre randomised controlled trial (REVISE-Diabesity ISRCTN00151053) investigating the efficacy, safety and tolerability of adding Endobarrier therapy, a 60 cm endoscopically implanted proximal intestinal liner, to (GLP-...

Citations

... This led to a total of 90 EndoBarrier-treated people with diabetes and at one year after EndoBarrier 80% maintained significant improvement. 18 Confidence in the longevity of EndoBarrier treatment would be increased further by improvement maintained beyond one year. We therefore aimed to follow our people with diabetes for a further two years to evaluate further the extent to which the benefits of EndoBarrier treatment were, or were not, sustained. ...
... COVID-19 was defined as a SARS-CoV-2 infection confirmed by quantitative PCR (qPCR) performed on nasopharyngeal samples obtained by trained personnel and/or by fulfilling clinical and radiological diagnostic criteria at hospital admission. Further descriptions of each dataset have been published previously [17]. ...
... We were recently able to demonstrate that by two years after EndoBarrier removal improvement was maintained in 73%. 19 We present here the results of assessment over a further year -at three years after removal of EndoBarrier. ...
... The NHS supports audits with clear guidance for the contributing centers on using routine clinical practice data submitted anonymously via the secure NHS network [18]. Clinicians participating in the ABCD COVID-19 audit submitted data for adults with pre-existing type 1 and type 2 diabetes admitted with COVID-19 from hospitals across the UK. ...
... We read with great interest the editorial detailing the likelihood of cardiovascular (CV) benefit from the triple fixed-dose combination (FDC) therapy for patients with type 2 diabetes mellitus. 1 Sodium-glucose cotransporter-2 inhibitors (SGLT2i) are preferred in view of their documented CV benefits. The FDC pill containing metformin, dipeptidyl peptidase-4 (DPP-4) inhibitor and SGLT2i has been approved by the US FDA. ...
... 1 It is well established that optimised treatment can improve microvascular and macrovascular risk for people with diabetes. [2][3][4][5][6] Nevertheless, in clinical practice many people with diabetes fail to achieve and maintain improvements in risk factors despite lifestyle advice and maximal doses of oral and injectable medications. 7 Roux-en-Y gastric bypass (RYGB) is more effective than intensive anti-diabetes medical therapy and this has led to a joint statement by international diabetes organizations recommending more frequent metabolic surgery in treatment of T2DM. ...
... The mechanism associated with the increased risk of amputation is not known, but clinicians may consider implementing a suitable alternative treatment in patients with a history of amputation or peripheral vascular disease or in patients who develop an amputation-preceding event (e.g., lower-extremity skin ulcer, infection, osteomyelitis, or gangrene) (66)(67)(68). Clinicians should also encourage patients taking SGLT2 inhibitors to remain hydrated and to engage in good foot care practices to minimize their risk of amputation. As with any treatment decisions, practitioners should weigh the balance of benefits and risks associated with SGLT2 inhibitors. ...
... In every recent year, new cardiovascular outcome studies are published, illuminating our understanding regarding diabetes medications with cardiovascular protection, and we have discussed these in our previous editorials. [1][2][3][4][5][6] In 2020 two new studies from the sodium glucose transporter 2 (SGLT2) inhibitor class and one from the glucagon-like peptide-1 receptor agonist (GLP-1RA) class of antidiabetic medications are worth highlighting. Each provided new information to help our understanding about the cardioprotective benefits of these classes so that we can further improve patient care. ...